Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
Top 10 S&P Stocks Of The Obama Presidency
Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April
Biotechnology: Can Trump Be A Catalyst? (Seeking Alpha)
Related AGN
FTC Keeps Pressure On Wall Street, Refiles Suit Against Allergan, Others
The Market In 5 Minutes: McDonald's, Halliburton Ramp Up Q4 Earnings Season
Biotechnology: Can Trump Be A Catalyst? (Seeking Alpha)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Dec 2016BMO CapitalInitiates Coverage OnMarket Perform
Dec 2016BTIG ResearchUpgradesNeutralBuy
Dec 2016Chardan CapitalUpgradesSellNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

View Comments and Join the Discussion!